Market revenue in 2023 | USD 491.7 million |
Market revenue in 2030 | USD 861.1 million |
Growth rate | 8.3% (CAGR from 2023 to 2030) |
Largest segment | Ultrasound |
Fastest growing segment | PAMG-1 Immunoassay |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pelvic exam, Ultrasound, Biochemical Markers, Uterine Monitoring, Nitazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN) |
Key market players worldwide | Qiagen NV, Hologic Inc, CooperSurgical, Abbott Laboratories, Biosynex, Sera Prognostics, Medix Biochemica, Clinical Innovations, NX Prenatal, IQ Products |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to preterm birth and prom testing market will help companies and investors design strategic landscapes.
Ultrasound was the largest segment with a revenue share of 31.83% in 2023. Horizon Databook has segmented the U.S. preterm birth and prom testing market based on pelvic exam, ultrasound, biochemical markers, uterine monitoring, nitazine test, ferning test, pooling, pamg-1 immunoassay, igfbp test, fetal fibronectin (ffn) covering the revenue growth of each sub-segment from 2018 to 2030.
The CDC also reported that although the rate declined from 2007 to 2014, it has increased since then due to many factors. Some of these factors are multiple pregnancies, consumption of illicit drugs & alcohol, and chronic conditions such as high blood pressure & diabetes.
Babies born preterm are at a greater risk of early death as compared to babies born later in pregnancy. It is one the significant causes of neonatal mortality in the country. Among all the reported cases of preterm births, 80% are unanticipated, 45% to 50% are unknown, and 30% are associated with Preterm Rupture of Membranes (PROM). Therefore, there is rising need for early diagnosis and treatment, facilitating high regional growth.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. preterm birth and prom testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. preterm birth and prom testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account